Big Sale Alert
25% OFF Entire Assortment!
Use Coupon Code: 25MAR
Mayne Pharma Group gains U.S. marketing approval for oral antibiotic
11-April-2013: Mayne Pharma Group has been given the green light by the U.S. Food and Drug Administration for the sale of its 200mg strength Doryx delayed-release tablet.
Warner Chilcott, the company's marketing and distribution partner for Doryx in the U.S., is expected to begin the launch of the oral antibiotic by July 2013.
Doryx tablets are delayed release oral formulations of doxycycline, which can be used to treat certain types of infections, severe acne, as well as an anti-malarial drug.
The product is already being sold in 75mg, 100mg and 150mg strengths in the U.S.
The second half of 2013 is expected to benefit from a return to revenue growth of Doryx compared to the first half of 2013 results.
Mayne Pharma held around A$30.4 million in cash at the end of December 2012.
Source: Proactive Investors Australia